Jasper Therapeutics, Inc. (NASDAQ:JSPR) Sees Significant Increase in Short Interest

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the target of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 2,000,000 shares, an increase of 8.7% from the August 15th total of 1,840,000 shares. Approximately 17.3% of the company’s stock are sold short. Based on an average trading volume of 188,600 shares, the days-to-cover ratio is currently 10.6 days.

Analysts Set New Price Targets

JSPR has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. Royal Bank of Canada dropped their price objective on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a report on Wednesday, August 14th. Stifel Nicolaus began coverage on Jasper Therapeutics in a report on Thursday, June 27th. They issued a “buy” rating and a $86.00 price objective on the stock. JMP Securities began coverage on Jasper Therapeutics in a research report on Monday, September 9th. They issued an “outperform” rating and a $70.00 target price for the company. Finally, Evercore ISI reissued an “outperform” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a research report on Monday, August 26th. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Jasper Therapeutics presently has a consensus rating of “Buy” and an average target price of $73.00.

Institutional Trading of Jasper Therapeutics

Hedge funds have recently modified their holdings of the business. American Century Companies Inc. increased its stake in Jasper Therapeutics by 27.1% in the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock valued at $322,000 after purchasing an additional 3,032 shares in the last quarter. Rhumbline Advisers purchased a new position in Jasper Therapeutics in the 2nd quarter valued at approximately $300,000. Bank of New York Mellon Corp purchased a new position in Jasper Therapeutics in the 2nd quarter valued at approximately $740,000. Virtu Financial LLC purchased a new position in Jasper Therapeutics in the 1st quarter valued at approximately $306,000. Finally, Ikarian Capital LLC purchased a new position in Jasper Therapeutics in the 1st quarter valued at approximately $3,088,000. 79.85% of the stock is owned by institutional investors and hedge funds.

Jasper Therapeutics Stock Performance

Jasper Therapeutics stock traded down $0.23 during mid-day trading on Wednesday, reaching $22.74. 187,200 shares of the company were exchanged, compared to its average volume of 139,842. Jasper Therapeutics has a twelve month low of $4.00 and a twelve month high of $31.01. The firm’s 50-day simple moving average is $19.52 and its two-hundred day simple moving average is $22.72. The firm has a market cap of $342.56 million, a PE ratio of -4.16 and a beta of 2.22.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.12. As a group, equities research analysts anticipate that Jasper Therapeutics will post -4.16 EPS for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.